UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 3, 2010
PEREGRINE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)
| Delaware | | 0-17085 | | 95-3698422 |
(State of other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Company Identification No.) |
| 14282 Franklin Avenue, Tustin, California 92780 |
| (Address of Principal Executive Offices) |
Registrant’s telephone number, including area code: (714) 508-6000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| o | Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 Enter into a Material Definitive Agreement.
On May 3, 2010, Peregrine Pharmaceuticals, Inc., a Delaware corporation, ( “Peregrine” or the “Company”) entered into two separate agreements (the “Agreements”) with Stason Pharmaceuticals, a privately-held U.S.-based pharmaceutical company (“Stason”) to develop the Company’s Tumor Necrosis Therapy (“TNT”) technologies in certain Asia-Pacific Economic Cooperation (APEC) countries. Under the terms of the Agreements, Stason is acquiring from Peregrine exclusive rights to its TNT technologies in certain Asia-Pacific Economic Cooperation (APEC) countries. The Agreements also include certain non-exclusive licenses for Peregrine's proprietary radiolabeling technologies and its fully-human NH S76 TNT antibody. The Company has retained exclusive rights to its TNT technologies in the United States, European Union countries, and other select countries internationally.
A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
Exhibit
Number
99.1 Press Release issued May 3, 2010
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | PEREGRINE PHARMACEUTICALS, INC. | |
| | | | |
| Date: May 4, 2010 | By: | /s/ Paul J. Lytle | |
| | | Paul J. Lytle | |
| | | Chief Financial Officer and Corporate Secretary | |
| | | | |
EXHIBIT INDEX
| Exhibit | |
| Number | Description |
| | |
| 99.1 | Press Release issued May 3, 2010 |
